BRIEF published on 12/17/2025 at 07:35, 7 months 26 days ago Sanofi Releases Q4 2025 Aide Mémoire Sanofi Financial Modeling Aide Mémoire Q4 2025 Forward-Looking
BRIEF published on 12/17/2025 at 07:35, 7 months 26 days ago Sanofi publie son aide-mémoire pour le quatrième trimestre 2025 Sanofi Modélisation Financière Aide Mémoire 4e Trimestre 2025 Tourné Vers L'avenir
PRESS RELEASE published on 12/17/2025 at 07:30, 7 months 26 days ago Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire » Sanofi annonce la mise en ligne du document 'Q4 2025 Aide mémoire' pour assister la communauté financière dans la modélisation des résultats trimestriels Communication Financière Résultats Trimestriels Sanofi Document Q4 2025
PRESS RELEASE published on 12/17/2025 at 07:30, 7 months 26 days ago Press release: Availability of the Q4 2025 Aide memoire Sanofi announces availability of Q4 2025 Aide memoire on the company's website for financial modeling purposes. Q4 2025 results to be published on January 29, 2026 Sanofi Results Aide Mémoire Financial Modelling Q4 2025
BRIEF published on 12/15/2025 at 07:10, 7 months 28 days ago Sanofi renonce à l'autorisation de mise sur le marché du tolebrutinib dans le traitement de la SEP progressive primaire Sclérose En Plaques Tolebrutinib Essai PPMS Étude PERSEUS Recherche Et Développement Chez Sanofi
BRIEF published on 12/15/2025 at 07:10, 7 months 28 days ago Sanofi Halts Pursuit of Regulatory Registration for Tolebrutinib in PPMS Multiple Sclerosis Tolebrutinib PPMS Trial PERSEUS Study Sanofi R&D
BRIEF published on 12/15/2025 at 07:10, 7 months 28 days ago Sanofi : résultats de l'étude PERSEUS sur le tolébrutinib décevants Sclérose En Plaques Sanofi Tolebrutinib Étude PERSEUS Résultats D'étude
BRIEF published on 12/15/2025 at 07:10, 7 months 28 days ago Sanofi: PERSEUS study results on tolebrutinib disappointing Study Results Multiple Sclerosis Sanofi Tolebrutinib PERSEUS Study
BRIEF published on 12/15/2025 at 07:05, 7 months 28 days ago Le dépôt de la demande d'autorisation de mise sur le marché du tolebrutinib de Sanofi est retardé. FDA Sclérose En Plaques Sanofi Tolebrutinib Retard Réglementaire
PRESS RELEASE published on 12/15/2025 at 07:05, 7 months 28 days ago Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis Sanofi updates on tolebrutinib in primary progressive multiple sclerosis, PERSEUS phase 3 study did not meet primary endpoint. Safety profile consistent. Financial impacts discussed Sanofi Tolebrutinib Primary Progressive Multiple Sclerosis PERSEUS Phase 3 Study Financial Considerations
Published on 08/12/2026 at 15:42, 4 hours 50 minutes ago Critical Elements 10,000-Meter Summer Drill Program at Rose West Resumes with Positive Results
Published on 08/12/2026 at 15:42, 4 hours 50 minutes ago Critical Elements redémarre son programme de forage estival de 10 000 mètres à Rose Ouest avec des résultats positifs
Published on 08/12/2026 at 15:00, 5 hours 32 minutes ago Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America
Published on 08/12/2026 at 14:45, 5 hours 47 minutes ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/12/2026 at 19:57, 34 minutes ago EQS-Adhoc: Hypoport SE: Hypoport SE resolves share buyback programme with a volume of up to EUR 10 million
Published on 08/12/2026 at 19:37, 54 minutes ago EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
Published on 08/11/2026 at 17:45, 1 day 2 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 2 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 2 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 2 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
